Drug Approval | January 26, 2024
Zydus receives USFDA’s final approval for Gabapentin Tablets, 300 mg and 600 mg
Gabapentin is indicated for the management of Postherpetic Neuraligia
Gabapentin is indicated for the management of Postherpetic Neuraligia
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis
The company has received five final approvals
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Lacosamide is indicated to treat partial-onset seizures
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
Subscribe To Our Newsletter & Stay Updated
